<?xml version="1.0" encoding="UTF-8"?>
<table-wrap position="float" id="tbl3">
 <label>Table 3</label>
 <caption>
  <p>Application of adjuvants in subunit vaccines.</p>
 </caption>
 <alt-text id="alttext0050">Table 3</alt-text>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th>Adjuvant</th>
    <th>Composition</th>
    <th>Mechanism</th>
    <th>Antibody responses and neutralizing antibody</th>
    <th>Cellular immune response</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td>Alum</td>
    <td>Aluminum hydroxide/Aluminum phosphate</td>
    <td>1. Promotes a strong Th2-biased response(humoral immune response)
     <break/>2. Depot effect
     <break/>3. Inflammatory response
     <xref rid="bib87" ref-type="bibr">
      <sup>87</sup>
     </xref>
    </td>
    <td>1. Induces MERS-CoV RBD-specific antibody responses and neutralizing antibodies (1:1600) in rhesus macaque; neutralizes pseudotyped MERS-CoV
     <xref rid="bib85" ref-type="bibr">
      <sup>85</sup>
     </xref>.
     <break/>2. Induces MERS-CoV RBD-specific antibody responses
     <xref rid="bib88" ref-type="bibr">
      <sup>88</sup>
     </xref>.
    </td>
    <td>No-report</td>
   </tr>
   <tr>
    <td colspan="5">Emulsions</td>
   </tr>
   <tr>
    <td>Freund’s adjuvant</td>
    <td>IFA: an water-in-oil emulsion formed by mixing mineral oil with an emulsifier
     <break/>CFA: killed bacteria 
     <italic>M. tuberculosis</italic> added to IFA
    </td>
    <td rowspan="2">1. Continuous release of immunogenic substances in oil droplets
     <break/>2. Inflammatory response
     <break/>3. Stimulates the production of antibodies
     <xref rid="bib91" ref-type="bibr">
      <sup>91</sup>
     </xref>
     <sup>,</sup>
     <xref rid="bib92" ref-type="bibr">
      <sup>92</sup>
     </xref>
     <sup>,</sup>
     <xref rid="bib93" ref-type="bibr">
      <sup>93</sup>
     </xref>
     <break/>
    </td>
    <td>Induces SARS-CoV RBD-specific antibody responses and neutralizing antibodies (&gt;1:10
     <sup>4</sup>/1:10
     <sup>2</sup>-10
     <sup>3</sup>) in mice; neutralizes pseudotyped and live SARS-CoV
     <xref rid="bib94" ref-type="bibr">
      <sup>94</sup>
     </xref>.
    </td>
    <td>Elicits SARS-CoV RBD-specific T cell responses in mice
     <xref rid="bib94" ref-type="bibr">
      <sup>94</sup>
     </xref>.
    </td>
   </tr>
   <tr>
    <td>Montanide ISA51</td>
    <td>IFA</td>
    <td>1. Induces MERS-CoV RBD-specific antibody responses and neutralizing antibodies (&gt;1:10
     <sup>3</sup>) in mice; neutralizes live MERS-CoV
     <xref rid="bib83" ref-type="bibr">
      <sup>83</sup>
     </xref>.
     <break/>2. Induces neutralizing antibodies(1:240±139) in mouse; neutralizes live MERS-CoV
     <xref rid="bib98" ref-type="bibr">
      <sup>98</sup>
     </xref>.
    </td>
    <td>No-report</td>
   </tr>
   <tr>
    <td>Sigma adjuvant system (SAS)</td>
    <td>Oil-in-water emulsion containing monophosphoryl lipid A</td>
    <td rowspan="2">1. Enhances antigen uptake at the injection site
     <break/>2. Induces the production of cytokines and chemokines
     <break/>3. Recruits immune cells to the injection site
     <xref rid="bib99" ref-type="bibr">
      <sup>99</sup>
     </xref>
     <sup>,</sup>
     <xref rid="bib100" ref-type="bibr">
      <sup>100</sup>
     </xref>
     <sup>,</sup>
     <xref rid="bib101" ref-type="bibr">
      <sup>101</sup>
     </xref>
    </td>
    <td>1. Induces SARS-CoV RBD-specific antibody responses and neutralizing antibodies (1:6.9×10
     <sup>5</sup>/1:1.6×10
     <sup>3</sup>) in mice; neutralizes pseudotyped and live SARS-CoV
     <xref rid="bib102" ref-type="bibr">
      <sup>102</sup>
     </xref>.
     <break/>2. Induces neutralizing antibodies (1:10
     <sup>2</sup>‒10
     <sup>3</sup>) in mice; neutralizes eight MERS-CoV strain
     <xref rid="bib103" ref-type="bibr">
      <sup>103</sup>
     </xref>.
    </td>
    <td>No-report</td>
   </tr>
   <tr>
    <td>MF59</td>
    <td>Squalene-based oil-in-water emulsion</td>
    <td>1. Induces MERS-CoV RBD-specific IgG subtype antibody (IgG1 and IgG2a) and neutralizing antibodies (1:100‒673) in mice; neutralizes live MERS-CoV
     <xref rid="bib104" ref-type="bibr">
      <sup>104</sup>
     </xref>.
     <break/>2. Induces MERS-CoV S1-specific IgG subtype antibody (IgG1 and IgG2a) and neutralizing antibodies (1:10
     <sup>3</sup>‒10
     <sup>4</sup>) in mice; neutralizes pseudotyped and live MERS-CoV
     <xref rid="bib105" ref-type="bibr">
      <sup>105</sup>
     </xref>.
    </td>
    <td>No significant increase in t-cell response
     <xref rid="bib106" ref-type="bibr">
      <sup>106</sup>
     </xref>.
    </td>
   </tr>
   <tr>
    <td colspan="5">Toll-Like Receptors (TLRs) agonists</td>
   </tr>
   <tr>
    <td>TLR3 agonist</td>
    <td>Double-stranded RNA (dsRNA) analogue</td>
    <td rowspan="3">1. The recognition of receptor stimulates innate immune responses such as antiviral and inflammatory responses
     <break/>2. Induce adaptive immune responses
     <break/>3. Activate immune cells and induce the production of Cytokines
     <xref rid="bib108" ref-type="bibr">
      <sup>108</sup>
     </xref>
     <sup>,</sup>
     <xref rid="bib109" ref-type="bibr">
      <sup>109</sup>
     </xref>
    </td>
    <td>No-Report</td>
    <td>1. Induces the expression of IFN-associated molecule, elicits T cell responses
     <xref rid="bib112" ref-type="bibr">
      <sup>112</sup>
     </xref>.
     <break/>2. Induces the production of type-I IFN, elicits T cell responses
     <xref rid="bib113" ref-type="bibr">
      <sup>113</sup>
     </xref>.
    </td>
   </tr>
   <tr>
    <td>TLR4 agonist</td>
    <td>LPS/MPLA</td>
    <td>Induces SARS-CoV S-specific antibody and virus-specific antibody (&gt;1:10
     <sup>4</sup>)
     <xref rid="bib118" ref-type="bibr">
      <sup>118</sup>
     </xref>.
    </td>
    <td>Induces the production of Th1 cytokines, elicits T cell responses
     <xref rid="bib118" ref-type="bibr">
      <sup>118</sup>
     </xref>.
    </td>
   </tr>
   <tr>
    <td>TLR9 agonist</td>
    <td>CpG DNA</td>
    <td>No-report</td>
    <td>1. Induces the production of IFN-a and IFN-γ, enhance NK cell cytotoxicity
     <xref rid="bib122" ref-type="bibr">
      <sup>122</sup>
     </xref>.
     <break/>2. Induces cytotoxicity T cells response and memory T cells response
     <xref rid="bib123" ref-type="bibr">
      <sup>123</sup>
     </xref>.
    </td>
   </tr>
   <tr>
    <td colspan="5">Stimulator of interferon genes (STING) agonists</td>
   </tr>
   <tr>
    <td>STING agonist</td>
    <td>cdGMP</td>
    <td>1. Activates the production of host defense molecules and cytokines
     <break/>2. Induces adaptive immune responses
     <xref rid="bib125" ref-type="bibr">
      <sup>125</sup>
     </xref>
     <sup>,</sup>
     <xref rid="bib126" ref-type="bibr">
      <sup>126</sup>
     </xref>
    </td>
    <td>Induces MERS-CoV RBD-specific IgG subtype antibody (IgG1 and IgG2a) and neutralizing antibodies (1:40‒320) in mice; neutralizes live MERS-CoV
     <xref rid="bib128" ref-type="bibr">
      <sup>128</sup>
     </xref>
     <sub>.</sub>
    </td>
    <td>Induces the production of IFN-
     <italic>γ</italic> and memory T cells response
     <xref rid="bib128" ref-type="bibr">
      <sup>128</sup>
     </xref>.
    </td>
   </tr>
  </tbody>
 </table>
</table-wrap>
